US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Artelo Biosciences Inc (ARTLW)
Artelo Biosciences Inc (ARTLW) ニュース

ARTLW

Artelo Biosciences (ARTLW)

Artelo Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARTLW

1

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/13	22 : 17	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ARTLW	Artelo Biosciences Inc
2024/03/05	06 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARTLW	Artelo Biosciences Inc
2024/03/02	08 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/05/20	06 : 46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/05/19	06 : 10	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/05/09	05 : 32	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/04/15	19 : 25	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/04/15	19 : 09	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/04/14	19 : 03	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/04/14	05 : 28	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/04/13	19 : 01	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/04/07	19 : 05	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/03/12	05 : 31	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/02/15	06 : 40	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/02/15	06 : 39	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ARTLW	Artelo Biosciences Inc
2020/02/15	06 : 39	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/11/18	22 : 30	GlobeNewswire Inc.	Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewe...	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/11/14	23 : 00	GlobeNewswire Inc.	Artelo Biosciences to Present at the Annual Investival Showcase in London	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/10/29	21 : 30	GlobeNewswire Inc.	Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART2...	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/10/22	22 : 00	GlobeNewswire Inc.	Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/09/18	21 : 00	GlobeNewswire Inc.	Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/07/16	05 : 01	GlobeNewswire Inc.	Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/06/26	02 : 00	GlobeNewswire Inc.	Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Optio...	NASDAQ:ARTLW	Artelo Biosciences Inc
2019/06/22	02 : 50	GlobeNewswire Inc.	Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq	NASDAQ:ARTLW	Artelo Biosciences Inc

Showing the most relevant articles for your search:NASDAQ:ARTLW

1

BPCE SFH Bpce Sfh 3.18% ...

NLBNPIT1UI16 20351221 21...

NLBNPIT1WZW6 20240920 500

Game chain Network

NLBNPIT1XVD3 20991231 91...

Uscf Sustainable Battery...

Leonteq Securities

Southern Cross Goldfields

NLBNPIT1XHM3 20240621 1.8

American Copper Developm... (QB)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約